The announcement that AIM listed ANGLE (55.5p) has submitted an application to the US FDA for its Parsortix® system seeking clearance for use with metastatic breast cancer patients is likely to generate significant interest in the shares.  The submission to the FDA is the culmination of five years’ work which has included extensive dialogue with the FDA and the development of over 400 technical reports and documents which have been included with the submission.

This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters. Get one week FREE trial with all our packages. Registration is quick and simple HERE.

Already a member, log in HERE.